Combining Automation And Defined Culture Conditions To Enable Rapid Manufacturing Of CAR-T Cells

Step into the world of rapid innovation with our automated cell manufacturing equipment, the Cocoon® Platform, and discover how it's transforming the landscape of CAR-T manufacturing.

The complex process associated with the manufacture of CAR-T cell therapies presents challenges that immensely impact patient accessibility to these treatments. Reducing the complexity of the manufacture is key.

Tamara J. Laskowski, Ph.D., shares how her team has developed an automated workflow that consolidates the critical steps required for transforming T cells into potent CAR-T cell therapies in just 72 hours.